Testosterone metabolism of equine single CYPs of the 3A subfamily compared to the human CYP3A4.

Cytochrome P450 enzymes (CYPs) are responsible for the phase I metabolism of drugs, xenobiotics and endogenous substances. Knowledge of single CYPs and their substrates is important for drug metabolism, helps to predict adverse effects and may prevent reduced drug efficacy in polypharmacy. In this study, three equine isoenzymes of the 3A subfamily, the equine flavoprotein NADPH-P450 oxidoreductase (POR), and the cytochrome b5 (CYB5) were cloned, sequenced and heterologously expressed in a baculovirus expression system. Testosterone, the standard compound for characterization of the human CYP3A4, was used to characterize the newly expressed equine CYPs. The metabolite pattern was similar in equine and the human CYPs, but the amounts of metabolites were isoform-dependent. All equine CYPs produced 2-hydroxytestosterone (2-OH-TES), a metabolite never described in equines. The main metabolite of CYP3A4 6β-hydroxytestosterone (6β-OH-TES) was measured in CYPs 3A95 and 3A97 with levels close to the detection limit. Ketoconazole inhibited 2-OH-TES in the human CYP3A4 and the equine CYP3A94 and CYP3A97 completely, whereas a 70% inhibition was found in CYP3A95. Testosterone 6β- and 2-hydroxylation was significantly different in the equine CYPs compared to CYP3A4. The expression of single equine CYPs allows characterizing drug metabolism and may allow prevention of drug-drug interactions.

[1]  Shiew-Mei Huang,et al.  Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[2]  M. Dacasto,et al.  Comparative expression of liver cytochrome P450-dependent monooxygenases in the horse and in other agricultural and laboratory species. , 2003, Veterinary journal.

[3]  Z. Dvořák,et al.  Dual Effects of Ketoconazole cis-Enantiomers on CYP3A4 in Human Hepatocytes and HepG2 Cells , 2014, PloS one.

[4]  E. Hodgson,et al.  Inhibition and activation of the human liver microsomal and human cytochrome P450 3A4 metabolism of testosterone by deployment-related chemicals. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[5]  M. Ishizuka,et al.  Characterization of equine cytochrome P450: role of CYP3A in the metabolism of diazepam. , 2016, Journal of veterinary pharmacology and therapeutics.

[6]  J S Harmatz,et al.  Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[7]  J. Tallkvist,et al.  Cytochrome P450 3A, NADPH cytochrome P450 reductase and cytochrome b5 in the upper airways in horse. , 2008, Research in veterinary science.

[8]  X. Su,et al.  Transcriptome analyses of insect cells to facilitate baculovirus-insect expression , 2016, Protein & Cell.

[9]  I. Cascorbi,et al.  Functional Gene Variants of CYP3A4 , 2014, Clinical pharmacology and therapeutics.

[10]  J. Schenkman,et al.  The many roles of cytochrome b5. , 2003, Pharmacology & therapeutics.

[11]  A. D. Rodrigues,et al.  Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[12]  L. Trepanier,et al.  Role of NADPH-Cytochrome P450 Reductase and Cytochrome-b5/NADH-b5 Reductase in Variability of CYP3A Activity in Human Liver Microsomes , 2009, Drug Metabolism and Disposition.

[13]  R. Auchus,et al.  Two surfaces of cytochrome b5 with major and minor contributions to CYP3A4-catalyzed steroid and nifedipine oxygenation chemistries. , 2014, Archives of biochemistry and biophysics.

[14]  A. Schinkel,et al.  A Critical Analysis of the Interplay between Cytochrome P450 3A and P-Glycoprotein: Recent Insights from Knockout and Transgenic Mice , 2011, Pharmacological Reviews.

[15]  N. Chauret,et al.  In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[16]  J B Houston,et al.  In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[17]  W. Thormann,et al.  Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans. , 2011, American journal of veterinary research.

[18]  M. Mevissen,et al.  Inhibition of in vitro metabolism of testosterone in human, dog and horse liver microsomes to investigate species differences. , 2015, Toxicology in vitro : an international journal published in association with BIBRA.

[19]  David Moore,et al.  Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions—an Industry Perspective , 2016, Drug Metabolism and Disposition.

[20]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[21]  F Peter Guengerich,et al.  Cytochromes P450, drugs, and diseases. , 2003, Molecular interventions.

[22]  M. Mevissen,et al.  Induction of cytochrome P450 enzymes in primary equine hepatocyte culture. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[23]  W. Thormann,et al.  In vitro evaluation of differences in phase 1 metabolism of ketamine and other analgesics among humans, horses, and dogs. , 2009, American journal of veterinary research.

[24]  Lingli Huang,et al.  Comparison of the substrate kinetics of pig CYP3A29 with pig liver microsomes and human CYP3A4. , 2011, Bioscience reports.

[25]  S. Stanley,et al.  Equine cytochrome P450 2C92: cDNA cloning, expression and initial characterization. , 2009, Archives of biochemistry and biophysics.

[26]  Diansong Zhou,et al.  Baculovirus Infected Insect Cells , 2010 .

[27]  M. Shimoda,et al.  In vitro cytochrome P450-mediated hepatic activities for five substrates in specific pathogen free chickens. , 2001, Journal of veterinary pharmacology and therapeutics.

[28]  W. Thormann,et al.  Enantioselective CE analysis of hepatic ketamine metabolism in different species in vitro , 2010, Electrophoresis.

[29]  T. Leeb,et al.  Comparative human-horse sequence analysis of the CYP3A subfamily gene cluster. , 2010, Animal genetics.

[30]  Jingjing Yu,et al.  Drug Disposition and Drug-Drug Interaction Data in 2013 FDA New Drug Applications: A Systematic Review , 2014, Drug Metabolism and Disposition.

[31]  C. Portier,et al.  Stereoselective biotransformation of ketamine in equine liver and lung microsomes. , 2008, Journal of veterinary pharmacology and therapeutics.

[32]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.

[33]  A. Demain,et al.  Production of recombinant proteins by microbes and higher organisms. , 2009, Biotechnology advances.

[34]  H. Ranson,et al.  Microarray and RNAi Analysis of P450s in Anopheles gambiae Male and Female Steroidogenic Tissues: CYP307A1 Is Required for Ecdysteroid Synthesis , 2013, PloS one.

[35]  S. Stanley,et al.  Complementary DNA cloning, functional expression and characterization of a novel cytochrome P450, CYP2D50, from equine liver. , 2008, Biochemical pharmacology.

[36]  J. Fink-Gremmels.  Implications of hepatic cytochrome P450-related biotransformation processes in veterinary sciences. , 2008, European journal of pharmacology.

[37]  S. Stanley,et al.  Molecular Cloning, Expression, and Initial Characterization of Members of the CYP3A Family in Horses , 2010, Drug Metabolism and Disposition.

[38]  U. Apte,et al.  Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer. , 2015, Advances in pharmacology.

[39]  B. Lake,et al.  Induction of drug metabolism: species differences and toxicological relevance. , 2008, Toxicology.

[40]  F. Walker,et al.  P450 reductase and cytochrome b5 interactions with cytochrome P450: effects on house fly CYP6A1 catalysis. , 2008, Insect biochemistry and molecular biology.

[41]  Thomas A Kost,et al.  Baculovirus as versatile vectors for protein expression in insect and mammalian cells , 2005, Nature Biotechnology.

[42]  B. Dick,et al.  In vitro metabolism of testosterone in the horse liver and involvement of equine CYPs 3A89, 3A94 and 3A95. , 2014, Journal of veterinary pharmacology and therapeutics.

[43]  I. A. Ross,et al.  Effects of oral androstenedione on steroid metabolism in liver of pregnant and non-pregnant female rats. , 2005, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[44]  M. Berenbaum,et al.  Structure and Function of Cytochrome P450S in Insect Adaptation to Natural and Synthetic Toxins: Insights Gained from Molecular Modeling , 2013, Journal of Chemical Ecology.

[45]  A. Kamen,et al.  Recombinant Protein Production in Large-Scale Agitated Bioreactors Using the Baculovirus Expression Vector System. , 2016, Methods in molecular biology.

[46]  R. Feyereisen,et al.  Evolution of insect P450. , 2006, Biochemical Society transactions.

[47]  P. Teale,et al.  Drug metabolism in the horse: a review. , 2011, Drug testing and analysis.

[48]  A. Y. Lu,et al.  Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[49]  F. Capolongo,et al.  Differential gene expression of CYP3A isoforms in equine liver and intestines. , 2012, Journal of veterinary pharmacology and therapeutics.

[50]  D. Greenblatt.  The ketoconazole legacy , 2014, Clinical pharmacology in drug development.

[51]  C. Flück,et al.  NADPH P450 oxidoreductase: structure, function, and pathology of diseases. , 2013, Pharmacology & therapeutics.

[52]  M. Mevissen,et al.  Heterologous Expression of Equine CYP3A94 and Investigation of a Tunable System to Regulate Co-Expressed NADPH P450 Oxidoreductase Levels , 2014, PloS one.